Screener / SEC EDGAR /CIK 0001906324 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

QuidelOrtho Corp QDEL

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 19, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 28, 2025 vs Dec 29, 2024

-70.5% to -33.7% (+36.8 pts)

“Research and development expense for fiscal year ended 2025 decreased by $32.5 million, or 14.9%, to $186.2 million from $218.7 million for the prior year, primarily due to lower third-party material and outside service spend, compensation costs and clinical costs related to cost-savings initiatives actioned in 2024.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 28, 2025 vs Dec 29, 2024

+26.7%

The MD&A has no sentence that names a cause for this change.

Revenue

Change, FY to Dec 28, 2025 vs Dec 29, 2024

-1.9%

“Labs revenue increased 6% compared to the prior year, primarily due to growth in reagents, consumables and services, partially offset by a decline in instrument revenue.”

Read it in the 10-K

“Immunohematology revenue increased 4% compared to the prior year, primarily due to reagent growth.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 -1.9%

    “Labs revenue increased 6% compared to the prior year, primarily due to growth in reagents, consumables and services, partially offset by a decline in instrument revenue.”

    Read it in the FY 2025 10-K

    “Immunohematology revenue increased 4% compared to the prior year, primarily due to reagent growth.”

    Read it in the FY 2025 10-K
  • FY 2024 -7.2%

    “The increase in Labs revenue was primarily related to growth in reagents, consumables and services, partially offset by decreased COVID-19 and non-core revenue compared to the prior year.”

    Read it in the FY 2024 10-K

    “Immunohematology revenue increased 2% compared to the prior year period, primarily due to reagent growth.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 +36.8 pts

    “Research and development expense for fiscal year ended 2025 decreased by $32.5 million, or 14.9%, to $186.2 million from $218.7 million for the prior year, primarily due to lower third-party material and outside service spend, compensation costs and clinical costs related to cost-savings initiatives actioned in 2024.”

    Read it in the FY 2025 10-K
  • FY 2024 -75.1 pts

    “Research and development expense for fiscal year ended 2024 decreased by $26.3 million, or 10.7%, to $218.7 million from $245.0 million for the prior year, primarily due to lower employee compensation costs and costs of outside services.”

    Read it in the FY 2024 10-K

Cash from operations

0 of 2 years explained
  • FY 2025 +26.7%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 -70.4%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.